Table 2. Individual patient... | American Society of Hematology

Table 2.

Individual patient characteristics

Patient no.	Age, y/sex	Disease	No. prior	WBC count (ANC), × 1000/μL	ABC, × 1000/μL on d 1	Platelet count, × 1000/μL on d 1	BM	dANC less than 500	Best response	ITD length	Variant allele, %	Karyotype
1	46/F	ref	3	4.3 (1.6)	1.5	9	10 F	d 16-57	50 PB	48	15	Unevaluable
2	43/M	ref	1	31.1 (5.6)	1.2	8	5 F	N/A	50 PB	24	15	Normal
3	39/M	rel	3	48.6 (1.0)	46	361	87	N/A	no	84	90	Normal
4	38/M	rel	3	65.9 (.7)	65	176	80	d 42-78	scb	99	35	Normal
5	54/M	rel	4	0.9 (0)	0.8	6	91	N/A	50 PB	51	45	t(2;17)
6	72/M	rel	4	1.8 (.04)	0	47	25	N/A	no	45	25	Normal
7	66/F	ref	2	15.3 (.5)	10	31	79	N/A	50 PB	27	46	t(2;12)
8	53/M	rel	4	2.3 (.8)	0.5	43	80	d 8-36	50 PB	18	45	Normal
9	53/M	ref	2	26.4 (1.1)	16	31	88	d 8-22	scb	21	42	Normal
10	59/M	ref	4	120 (7.2)	110	44	96	N/A	scb/CR	D835Y		Normal
11	64/M	rel	2	15.8 (11.2)	1.7	41	14	N/A	scb	21	3	Normal
12	67/M	rel	6	23 (.23)	21	14	88	N/A	scb	33	88	t(6;9)
13	78/M	AML	0	81.4 (5.7)	46	23	56	N/A	scb	105	35	Normal
14	66/M	ref	6	37.5 (0)	37	11	93	N/A	50 PB	36	49	Unevaluable
15	67/M	CMML	0	8.6 (4.9)	0	1	< 5	N/A	no	D835Y		Normal
16	76/F	AML	0	49.2 (3.4)	13	14	70	N/A	no	54	4	Inv(16)
17	40/F	rel	2	83.2 (2.5)	66	619	82	N/A	no	189	11	7q-t(9;22)
18	78/M	rel	2	5.4 (.11)	4.5	21	80	N/A	50 PB	27	38	Normal
19	66/F	ref	3	116.5 (2.3)	94	32	76	N/A	no	93	39	Normal
20	29/F	rel	2	46.2 (0)	71	80	93	N/A	scb	42	100	Unevaluable

Patient no.	Age, y/sex	Disease	No. prior	WBC count (ANC), × 1000/μL	ABC, × 1000/μL on d 1	Platelet count, × 1000/μL on d 1	BM	dANC less than 500	Best response	ITD length	Variant allele, %	Karyotype
1	46/F	ref	3	4.3 (1.6)	1.5	9	10 F	d 16-57	50 PB	48	15	Unevaluable
2	43/M	ref	1	31.1 (5.6)	1.2	8	5 F	N/A	50 PB	24	15	Normal
3	39/M	rel	3	48.6 (1.0)	46	361	87	N/A	no	84	90	Normal
4	38/M	rel	3	65.9 (.7)	65	176	80	d 42-78	scb	99	35	Normal
5	54/M	rel	4	0.9 (0)	0.8	6	91	N/A	50 PB	51	45	t(2;17)
6	72/M	rel	4	1.8 (.04)	0	47	25	N/A	no	45	25	Normal
7	66/F	ref	2	15.3 (.5)	10	31	79	N/A	50 PB	27	46	t(2;12)
8	53/M	rel	4	2.3 (.8)	0.5	43	80	d 8-36	50 PB	18	45	Normal
9	53/M	ref	2	26.4 (1.1)	16	31	88	d 8-22	scb	21	42	Normal
10	59/M	ref	4	120 (7.2)	110	44	96	N/A	scb/CR	D835Y		Normal
11	64/M	rel	2	15.8 (11.2)	1.7	41	14	N/A	scb	21	3	Normal
12	67/M	rel	6	23 (.23)	21	14	88	N/A	scb	33	88	t(6;9)
13	78/M	AML	0	81.4 (5.7)	46	23	56	N/A	scb	105	35	Normal
14	66/M	ref	6	37.5 (0)	37	11	93	N/A	50 PB	36	49	Unevaluable
15	67/M	CMML	0	8.6 (4.9)	0	1	< 5	N/A	no	D835Y		Normal
16	76/F	AML	0	49.2 (3.4)	13	14	70	N/A	no	54	4	Inv(16)
17	40/F	rel	2	83.2 (2.5)	66	619	82	N/A	no	189	11	7q-t(9;22)
18	78/M	rel	2	5.4 (.11)	4.5	21	80	N/A	50 PB	27	38	Normal
19	66/F	ref	3	116.5 (2.3)	94	32	76	N/A	no	93	39	Normal
20	29/F	rel	2	46.2 (0)	71	80	93	N/A	scb	42	100	Unevaluable

No. prior indicates number of prior regimens; ABC, absolute blast count; BM bone marrow blast percentages before treatment; dANC, nadir days ANC is less than 500 to 1000/μL; ref, refractory AML; F, fibrosis; 50 PB, 50% reduction in ABC in peripheral blood; N/A, not assessable; rel, relapsed AML; scb, significant clinical benefit (see “Treatment plan”); CR, complete response

View Large

This Feature Is Available To Subscribers Only